Taiwan Liposome Company's Liver Cancer Drug Put on Fast Track in China

by Richard Daverman, PhD

March 18, 2013 -- Lipotecan®, an innovative liver cancer drug developed by Taiwan Liposome Company, was accepted into the SFDA’s Green Path program, a fast-track approval process. TLC said Lipotecan is a new chemical entity with multiple mechanisms of action against tumors that has shown positive results in ex-China Phase II trials. TLC expects to start a China Phase II trial later this year. More details....

Stock Symbol: (TW: 4152)